Neuracura Therapeutics · Alzheimer’s research

A different approach.A focus on function.

Investigating Bryostatin-1 to support the connections behind cognition and everyday life in moderately severe Alzheimer’s disease.

Explore the science

An investigational program. Clinical benefit remains to be established.

Our purpose

Everyday abilities.
Extraordinary meaning.

Alzheimer’s affects more than memory. It changes how people communicate, take part in daily activities, and live alongside the people they love.

The science

Start with
the connections.

Synapses are the connections through which neurons communicate. Their loss is closely associated with cognitive impairment in Alzheimer’s disease.

Bryostatin-1 activates protein kinase C pathways, including PKCε. Preclinical research supports a hypothesis that these pathways could promote synaptic plasticity and repair. Whether this translates into meaningful benefit for patients requires clinical confirmation.

Mechanism

A synaptic focus

A research approach centered on the biological pathways involved in neuronal connections, cognition, and function.

Clinical foundation

Evidence to build on

Prior Alzheimer’s Phase 2 studies reported encouraging signals in selected patient subgroups. Overall efficacy has not been established.

Supply pathway

A new route to synthesis

A scalable chemical synthesis of Bryostatin-1 was published in 2017, providing a research pathway beyond reliance on marine supply.

Mechanistic findings are preclinical. Prior subgroup findings, including exploratory and post-hoc analyses, are a rationale for further research and do not establish clinical efficacy.

Clinical development

A focused question.
A purposeful study.

BRYGHT-AD · Proposed Phase 2

The proposed BRYGHT-AD study is designed to test Bryostatin-1 in the patient population associated with encouraging signals in earlier research, measuring cognition alongside everyday function.

Study population
Moderately severe Alzheimer’s disease; MMSE 10–14; not receiving memantine.
Proposed design
Randomized, double-blind, placebo-controlled study with a planned enrollment of 100 participants.
Cognition
Proposed primary endpoint: Severe Impairment Battery (SIB) total score at Week 28.
Everyday function
Proposed secondary endpoint: change in ADCS-ADL-Severe at Week 28.
Prospective trial site
Ace Alzheimer Center Barcelona (Fundació ACE), Spain.

Study details are planning proposals, subject to final protocol, statistical analysis plan, and applicable approvals. This page is not a recruitment announcement.

Prospective clinical partner

Deep experience.
Close to patients.

Ace Alzheimer Center Barcelona is a nonprofit foundation working across dementia care, research, training, and support for families.

Its multidisciplinary clinical infrastructure and established patient relationships underpin Neuracura’s proposed collaboration.

1995

Foundation established

9,337

People served by its Diagnostic Unit in 2025

31

Active pharmacological trials in 2025

Source: Ace Alzheimer Center Barcelona, Activity Report 2025.

Further reading

The full picture.

Explore the program rationale and scientific background, alongside ACE’s own activity report.

Program overviewOur focus, the clinical rationale, and the next research question.

Neuracura is developing an investigational Bryostatin-1 program focused on moderately severe Alzheimer’s disease. The objective is to study whether biological pathways associated with synaptic function could support cognition and everyday abilities.

The proposed BRYGHT-AD study would prospectively assess a defined patient population informed by earlier subgroup findings. Its design and timing remain subject to final protocol and applicable approvals. Clinical benefit has not been established.

Scientific & clinical backgroundFrom early research to the proposed BRYGHT-AD study.

Bryostatin-1 was originally isolated from a marine organism and investigated in National Cancer Institute oncology studies. Subsequent research examined its effects on protein kinase C pathways and synaptic biology.

Preclinical findings support further investigation of synaptic plasticity and repair. Prior Alzheimer’s trials reported signals in selected subgroups, including patients with moderately severe disease. Some analyses were exploratory or post hoc; the findings require prospective confirmation.

Prior human exposure does not establish that the drug is safe or effective for Alzheimer’s disease. The proposed study aims to evaluate cognition and daily function under a defined clinical protocol.

Ace Alzheimer Center Barcelona

The foundation’s clinical care and research activity report for 2025. · PDF

PDF

Start a conversation

Learn more about Neuracura.

For scientific, partnership, and general inquiries.

info@neuracura.com